News Headlines Article

Hepatitis C drug companies Presidio, BioCryst kill merger deal
San Francisco Business Times

Presidio Pharmaceuticals Inc.’s $101 million stock merger with BioCryst Pharmaceuticals Inc. is dead. Despite both companies working in the hot hepatitis C drug-development space, San Francisco-based Presidio and BioCryst (NASDAQ: BCRX) of Research Triangle Park, N.C., killed the deal Friday. A conference call and webcast on the merger’s dissolution, however, isn’t scheduled until Dec. 7.